Business
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
- PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. co...
About this update from Viridian Metals Inc
[{"type":"text","content":"Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwdoublebottom { border-bottom: double black 2.25pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadb4 { padding-bottom: 5px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl4 { padding-left: 20px }\n.bwpadl8 { padding-left: 40px }\n.bwpadr0 { padding-right: 0px }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignm { vertical-align: middle }\n.bwwidth1 { width: 1% }\n.bwwidth100 { width: 100% }\n.bwwidth12 { width: 12% }\n.bwwidth14 { width: 14% }\n.bwwidth3 { width: 3% }\n.bwwidth4 { width: 4% }\n.bwwidth57 { width: 57% }\n.bwwidth66 { width: 66% }\n.bwwidth8 { width: 8% }\n \n\n\n\n\n - PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch -\n \n\n\n\n - Marketing Authorization Application (MAA) for veligrotug for TED submitted to the European Medicines Agency (EMA) in January 2026 -\n \n\n\n\n ­­ - Phase 3 topline data readout for subcutaneous elegrobart (VRDN‑003) REVEAL‑1 and REVEAL‑2 studies on track for Q1 and Q2 2026 in active and chronic TED, respectively -\n \n\n\n\n - Advanced VRDN-008 into phase 1 clinical trial in healthy volunteers; data on track for 2H 2026 -\n \n\n\n\n - Strong balance sheet with cash, cash equivalents, and short-term investments of $875 million as of December 31, 2025 -\n \n\n\n\n - Based on existing cash, potential near-term milestones from 2025 royalty agreement, and anticipated commercial revenues, if both veligrotug and elegrobart are approved, the company expects current business plans to be funded through profitability -\n \n\n\n\n\n Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially ...